跳至主要内容
临床试验/NCT00174668
NCT00174668已完成3 期

52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy

Sanofi2 个研究点 分布在 2 个国家目标入组 311 人开始时间: 2004年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Sanofi
入组人数
311
试验地点
2
主要终点
HbA1c

研究概览

简要总结

Primary objective:

The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change in glycated hemoglobin A1c (HbA1c), from baseline to endpoint.

Secondary objectives:

Secondary study objectives are to compare the intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of blood glucose (BG) values (fasting, pre-/postprandial (ppBG), nocturnal, mean daily, fasting plasma glucose), daily BG profiles, BG and HbA1c response rates (predefined), hypoglycemic events, adverse events, change of late diabetes complications, weight, body-mass-index, course of total daily insulin dose and adjustment, blood lipid profile, microalbuminuria, standard lab and quality of life/treatment satisfaction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously

干预措施: Insulin Glulisine (Drug)

1

Experimental

Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously

干预措施: Insulin Glargine (Drug)

2

Active Comparator

Two daily injection conventional insulin therapy

干预措施: Insulin Therapy (Drug)

结局指标

主要结局

HbA1c

时间窗: From baseline to study endpoint

Self monitored BG (SMBG) values

时间窗: During the whole treatment phase

Body weight/body mass index (BMI)

时间窗: From baseline to study endpoint and all other visits

Fasting blood lipid profile

时间窗: From baseline to study endpoint and all other visits

Urine albumin

时间窗: From baseline to study endpoint and all other visits

Total daily insulin dose

时间窗: From baseline to study endpoint

次要结局

  • Vital signs(From baseline to study endpoint and all other visits)
  • Adverse events(Throughout the study,)
  • Standard laboratory tests(From baseline to study endpoint and all other visits)
  • Physical examination(From baseline to study endpoint and all other visits)

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验